Press Release

View printer-friendly version

<<  Back

Karyopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference

− Fireside Chat Scheduled for Tuesday, February 25, 2020, at 11:30 a.m. ET −

NEWTON, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 11:30 a.m. ET in NYC.

A live webcast of the fireside chat can be accessed on the "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the fireside chat.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. Karyopharm recently submitted a New Drug Application to the FDA seeking accelerated approval for XPOVIO in patients with diffuse large B-Cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com

Contacts:

Investors:
Karyopharm Therapeutics Inc.
Ian Karp, Vice President, Investor and Public Relations
857-297-2241 | ikarp@karyopharm.com

Media:
FTI Consulting
Simona Kormanikova or Robert Stanislaro
212-850-5600 |Simona.Kormanikova@fticonsulting.com or robert.stanislaro@fticonsulting.com

karyo.jpg

Source: Karyopharm Therapeutics Inc.